Second and third TNF inhibitors in European patients with axial spondyloarthritis: effectiveness and impact of the reason for switching.

ABSTRACT:

Objective

To investigate real-world effectiveness of tumor necrosis factor inhibitors (TNFi) in patients with axial spondyloarthritis (axSpA) and the association with (i) treatment line (second and third TNFi-series) and (ii) reason for withdrawal from the preceding TNFi [lack of efficacy (LOE) vs adverse events (AE)].

Methods

Prospectively collected routine care data from 12 European registries were pooled. Rates for 12-month drug retention and 6-month remission [Ankylosing Spondylitis Disease Activity Score C-reactive protein inactive disease (ASDAS-ID)] were assessed in second and third TNFi-series and stratified by withdrawal reason.

Results

We included 8254 s and 2939 third TNFi-series; 12-month drug retention rates were similar (71%). Six-month ASDAS-ID rates we

SUBMITTER: Linde L 

PROVIDER: S-EPMC11215991 | biostudies-literature | 2024 Jul

REPOSITORIES: biostudies-literature